We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone
Read MoreHide Full Article
For Immediate Release
Chicago, IL –April 4, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , Royal Dutch Shell , Celgene , Advanced Micro Devices (AMD - Free Report) and The Blackstone Group (BX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Pfizer, Royal Dutch-Shell and Celgene
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, Royal Dutch Shell and Celgene. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer’s shares have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (18.8% vs. 13.3%). Pfizer expects continued strong growth of key product franchises, including Ibrance, Eliquis, Xeljanz and Xtandi in 2019. However, loss of exclusivity on key drugs in the United States., mainly Lyrica and currency headwinds are expected to significantly hurt its 2019 sales.
Other top-line headwinds are weak sales in the EH segment, pricing pressure and rising competition. To offset the threat of generic competition, Pfizer is strengthening its pipeline as well as oncology portfolio. Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Bavencio, though currently approved for two small indications, is being considered a key long-term growth driver for Pfizer if it can gain label expansion approvals.
Shares ofbuy-ranked Royal Dutch Shell have lost -8.2% in the last six months, underperforming the Zacks Integrated Oil industry’s loss of -7.4% during the same period. However, the stock is poised for strong performance in 2019. The integrated behemoth's recent results have been driven by robust commodity prices and higher downstream earnings. Shell’s upstream unit profit has rebounded strongly thanks to steady commodity price recovery, while the integrated gas business — consisting of BG Group activities — impressed on the back of pricing gains.
Importantly, the Anglo-Dutch company's position as a key supplier of LNG should benefit its long-term cash flow growth. Consequently, Shell is likely to offer substantial upside from the current price levels and is viewed as a preferred supermajor to own now.
Celgene’s shares have gained 10.1% in the last three months, outperforming the Zacks Biomedical and Genetics industry's increase of 7.5%. Celgene’s key growth driver, Revlimid continues to drive revenues. Robust performance of psoriasis drug, Otezla is also boosting performance. Investors are focusing on the company’s recent merger agreement with Bristol-Myers Squibb Company. Per the terms, Celgene shareholders will receive 1.0 share of Bristol-Myers and $50.00 in cash for each share held.
Meanwhile, Celgene is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. The company is focused on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020.
Other noteworthy reports we are featuring today include Advanced Micro Devices and The Blackstone Group.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone
For Immediate Release
Chicago, IL –April 4, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , Royal Dutch Shell , Celgene , Advanced Micro Devices (AMD - Free Report) and The Blackstone Group (BX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Pfizer, Royal Dutch-Shell and Celgene
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, Royal Dutch Shell and Celgene. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pfizer’s shares have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (18.8% vs. 13.3%). Pfizer expects continued strong growth of key product franchises, including Ibrance, Eliquis, Xeljanz and Xtandi in 2019. However, loss of exclusivity on key drugs in the United States., mainly Lyrica and currency headwinds are expected to significantly hurt its 2019 sales.
Other top-line headwinds are weak sales in the EH segment, pricing pressure and rising competition. To offset the threat of generic competition, Pfizer is strengthening its pipeline as well as oncology portfolio. Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Bavencio, though currently approved for two small indications, is being considered a key long-term growth driver for Pfizer if it can gain label expansion approvals.
(You can read the full research report on Pfizer here >>>).
Shares ofbuy-ranked Royal Dutch Shell have lost -8.2% in the last six months, underperforming the Zacks Integrated Oil industry’s loss of -7.4% during the same period. However, the stock is poised for strong performance in 2019. The integrated behemoth's recent results have been driven by robust commodity prices and higher downstream earnings. Shell’s upstream unit profit has rebounded strongly thanks to steady commodity price recovery, while the integrated gas business — consisting of BG Group activities — impressed on the back of pricing gains.
Importantly, the Anglo-Dutch company's position as a key supplier of LNG should benefit its long-term cash flow growth. Consequently, Shell is likely to offer substantial upside from the current price levels and is viewed as a preferred supermajor to own now.
(You can read the full research report on Royal Dutch Shell here >>>).
Celgene’s shares have gained 10.1% in the last three months, outperforming the Zacks Biomedical and Genetics industry's increase of 7.5%. Celgene’s key growth driver, Revlimid continues to drive revenues. Robust performance of psoriasis drug, Otezla is also boosting performance. Investors are focusing on the company’s recent merger agreement with Bristol-Myers Squibb Company. Per the terms, Celgene shareholders will receive 1.0 share of Bristol-Myers and $50.00 in cash for each share held.
Meanwhile, Celgene is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. The company is focused on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020.
(You can read the full research report on Celgene here >>>).
Other noteworthy reports we are featuring today include Advanced Micro Devices and The Blackstone Group.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.